Rejuvenate Biomed's potential drug candidate combats sarcopenia in older adults
Rejuvenate Biomed - 21-Feb-2024Phase 1b trial shows RJx-01's ability to improve muscle strength, function, and fatigue resistance
Join the club for FREE to access the whole archive and other member benefits.
Biomedical company researching the biology of aging and developing drugs for age related diseases.
Subsequently, she established Rejuvenate Biomed, the independent Belgium based clinical stage R&D company and spin-out from Janssen Pharmaceutical companies of Johnson and Johnson, in October 2017. The company aims to increase the healthy years of life, also referred to as healthspan, by repositioning prescription drugs to the field of healthy ageing and age-related disease specifically. Their first entry to market is Sarcopenia, a newly established muscle failure disease (ICD-10 M62.84). They are ready to start their Phase II studies in 2020.
Visit website: https://www.rejuvenatebiomed.com/en
Details last updated 09-Nov-2020
Phase 1b trial shows RJx-01's ability to improve muscle strength, function, and fatigue resistance
Some really exciting developments with quite a few in clinical trials
Accelerates clinical trial plans for its lead candidate Rlx-01 targeting age-related muscle failure